The first 2 authors contributed equally to this work.
p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection
Version of Record online: 23 JUN 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 19, pages 4554–4563, 1 October 2009
How to Cite
Wang, X.-M., Yang, L.-Y., Guo, L., Fan, C. and Wu, F. (2009), p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer, 115: 4554–4563. doi: 10.1002/cncr.24494
- Issue online: 17 SEP 2009
- Version of Record online: 23 JUN 2009
- Manuscript Revised: 12 FEB 2009
- Manuscript Accepted: 12 FEB 2009
- Manuscript Received: 30 SEP 2008
- National Key Technology R&D Program of China. Grant Numbers: 2001BA703B04, 2004BA703B02
- National Basic Research Program of China. Grant Number: 2004CB720303
- National Natural Science Foundation for Distinguished Young Scholars of China. Grant Number: 30328028
- National High Technology Research and Development Program of China. Grant Number: 2006AA02Z4B2
- hepatocellular carcinoma;
- hepatic resection;
Currently, the role of p53-induced RING-H2 protein (PIRH2) in the development of hepatocellular carcinoma (HCC) remains unknown. The objective of this retrospective study was to investigate the expression of PIRH2 and its relation to prognosis in patients with HCC after hepatic resection.
Reverse transcriptase-polymerase chain reaction (RT-PCR), quantitative real-time RT-PCR, and Western blot analyses were used to detect expression levels of PIRH2 in 30 samples of HCC tissue and paracarcinomatous liver tissue (PCLT) and in 5 samples of normal liver tissue (NL). In addition, immunohistochemical analysis was performed on 122 HCC specimens and follow-up information data from those patients were reviewed.
Both messenger RNA and protein expression levels of PIRH2 were elevated significantly in HCC tissues compared with PCLT and NL tissues. The increased PIRH2 expression was correlated with vein invasion, Edmondson-Steiner grade, TNM stage, and multiple tumor nodes (P<.05). It is noteworthy that the patients with HCC who had high PIRH2 expression had shorter overall survival and disease-free survival than the patients who had low PIRH2 expression (median survival, 280 days vs 372 days; P = .0002; median disease-free survival, 220 days vs 310 days; P = .0016). Multivariate Cox regression analysis revealed that high PIRH2 expression was an independent prognostic factor for patients with HCC (relative risk, 1.792; P = .009).
The current data revealed that increased expression of PIRH2 was correlated with poor survival in patients with HCC, indicating that PIRH2 is a novel prognostic marker for HCC. Cancer 2009. © 2009 American Cancer Society.